Biotechnology

SKB BIO

Sichuan Kelun Biotech Obtains Approval to Begin Clinical Trials for PD-1xVEGF Bispecific Antibody SKB118

KailunboTai's Sac-TMT Supplemental New Drug Application Accepted for Review by NMPA

Sichuan Kelun Biotech Submits New Indication Application for TROP2 ADC

CordenPharm Presents Three Clinical Studies at ASCO Annual Meeting

CordenPharma's Sac-TMT in Combination with Merck's Keytruda Shows Positive Phase II Clinical Trial Results for Cervical and Ovarian Cancer

CLSA Adjusts Sales and Profit Forecasts for Kolon Biotech But Maintains Overweight Rating

Goldman Sachs Reiterates Buy Rating on Kolon Biotech, Sees Strong Prospects for Core Product

Colen Biopharma's Self-developed Novel Bispecific Antibody-Drug Conjugate SKB103 Approved for Clinical Trials by NMPA

Goldman Sachs Publishes Report on Kolon Biotech-B's Performance and Forecast

UBS Reports on Kexium Biologics' Performance and Adjusts Target Price

SKB BIO-B released FY2025 Q3 earnings on March 23 (BJT), actual revenue HKD 605.33 M, actual EPS HKD -0.5549

SKB BIO-B released FY2025 9 Months Earnings on March 23 (BJT), actual revenue HKD 1.634 B, actual EPS HKD -1.2447

SKB BIO-B released FY2025 Q4 earnings on March 23 After-Market (BJT), actual revenue HKD 615.77 M, actual EPS HKD 0

SKB BIO-B released FY2025 Annual Earnings on March 23 After-Market (BJT), actual revenue HKD 2.249 B (forecast HKD 2.16 B), actual EPS HKD -1.8108 (forecast HKD -2.3935)

Kolon Biologics-B Revenue Growth, Net Loss Widened in 2025

KoLunBio Releases sacituzumab tirumotecan Lung Cancer Treatment Data

KoColen Biotech to Announce Final Analysis Results of Key Clinical Study of Locascertamab at the European Lung Cancer Congress

SKB BIO-B to Release FY2025 Earnings on March 23 After-Market (BJT), Forecast Revenue HKD 2.198 B, EPS HKD -2.3943

Kolon Biologics-B enters into a Marketing Management Service Framework Agreement with Kolon Kaixin Group

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

06990

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received IND approval from China's National Medical Products Administration for SKB118, a bispecific antibody targeting PD-1 and VEGF for advanced solid tumors. This drug aims to enhance T-cell function and inhibit tumor blood supply. Kelun-Biotech's collaboration with Crescent Biopharma supports its development in Greater China, while a global trial is ongoing in the U.S. Analysts rate the stock (HK:6990) as a Buy with a price target of HK$526. The company focuses on innovative oncology therapies in the biopharmaceutical sector.

Tip Ranks

Crescent Biopharma

Kelun-Biotech Wins China IND Approval for Bispecific Cancer Antibody SKB118

02509

603259

WXXWY

01801

JPMorgan's report highlights the National Healthcare Security Administration's new plan for the 2026 National Reimbursement Drug List, which allows drugs to apply for NRDL inclusion before formal approval. This change is expected to enhance the commercialization prospects for innovative drug developers in China. The report identifies INNOVENT BIO, WUXI APPTEC, WUXI XDC, and SKB BIO as top picks, benefiting from clearer pricing rules and faster market access for high-priced drugs.

AASTOCKS News

QYUNS-B

WuXi AppTec

WuXi Biologics

WUXI APPTEC

WUXI BIO

TEDA BIOMEDICAL

INNOVENT BIO

WUXI XDC

ChinaAMC CSI Biotechnology Theme ETF

China Southern Hang Seng Biotech ETF(QDII)

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Penghua SSE STAR Biology and Medicine ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

ChinaAMC SSE STAR Biology and Medicine ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Huaan Hang Seng Biotech ETF

Tianhong CNI BIOMEDICINE ETF

E Fund CSI 300 Health Care ETF

China Merchants CSI Biotechnology Theme ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Yinhua CSI Innovative Drugs Industry ETF

Guotai CSI Bio-medicine ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Bosera Hang Seng SCHK Innovative Drug Select ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Penghua CSI HK Connect Health Care Composite ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

JPMorgan Chase

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO , WUXI APPTEC , WUXI XDC , SKB BIO

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that the sNDA for sacituzumab tirumotecan (sac-TMT) in combination with pembrolizumab has been accepted for review by the NMPA in China. This application targets first-line treatment for PD-L1-positive NSCLC patients. The acceptance follows positive results from the OptiTROP-Lung05 Phase III study, which met its primary endpoint of progression-free survival. This marks the fifth indication for sac-TMT to enter the NMPA's priority review process, potentially expediting approval.

prnewswire

Merck

06:40 ETThe sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First‑Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA

LEGN

Kelun-Biotech will present results from three clinical studies at the 2026 ASCO Annual Meeting in Chicago, scheduled for May 29 to June 2. The studies include data on sacituzumab tirumotecan (sac-TMT) for advanced non-small cell lung cancer, lunbotinib fumarate for RET fusion-positive NSCLC, and SKB500 for solid tumors. Abstracts will be published on May 21, 2026. Sac-TMT is a key product targeting various advanced solid tumors and has received multiple approvals in China, while lunbotinib is under review for RET-positive NSCLC treatment.

Legend Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

20:53 ETKelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 ASCO Annual Meeting

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced a commitment of RMB690 million to structured deposits with China Zheshang Bank and Bank of China. This move aims to enhance returns on idle funds while preserving capital, as the products are principal-guaranteed with floating returns. The transactions exceed the disclosure threshold under Hong Kong listing rules, requiring reporting. The company’s treasury management strategy may modestly improve interest income without affecting its core biopharmaceutical operations. Analysts rate the stock as a Buy with a target price of HK$526.00.

CZBANK

BANK OF CHINA

Bank Of China

BOC HONG KONG

Bank of China

Kelun-Biotech Commits RMB690 Million to Structured Deposits in Treasury Move

09926

06181

01177

00100

02513

03317

06869

01772

SKB BIO(06990) rose 6.97%, with a trading turnover 458.1 Million HKD, and a year-to-date rose 32.3%. AKESO(09926) rose 6.89%, with a trading turnover 1.7 Billion HKD, and a year-to-date rose 30.4%. MINIMAX-W(00100) fell 10.88%, with a trading turnover 1.9 Billion HKD, and a year-to-date rose 413.6%. KNOWLEDGE ATLAS(02513) fell 8.54%, with a trading turnover 1.9 Billion HKD, and a year-to-date rose 646.1%.

SKB BIO(06990.HK)

Kelun-Biotech Wins China IND Approval for Bispecific Cancer Antibody SKB118

JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO , WUXI APPTEC , WUXI XDC , SKB BIO

06:40 ETThe sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First‑Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA

20:53 ETKelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 ASCO Annual Meeting

Kelun-Biotech Commits RMB690 Million to Structured Deposits in Treasury Move

Top 5 HK Stock Gainers/Losers (>100B) (4.15)